Spectroscopy and Electrochemistry of Cobalt(III) Schiff Base Complexes
Abstract
The structural, spectroscopic, and electrochemical properties of cobalt(III) derivatives of acacen (H_2acacen = bis(acetylacetone) ethylenediimine) and related ligands have been investigated. Electronic structure calculations indicate that the absorption between 340 and 378 nm in Co^(III)(acacen) spectra is attributable to the lowest π−π* intraligand charge-transfer transition. Equatorial ligand substitutions affect reduction potentials less than axial ligand changes, consistent with an electronic structural model in which d_(z^2) is populated in forming cobalt(II). The crystal structure of [Co(3-Cl-acacen)(NH_3)_2]BPh_4 has been determined: The compound crystallizes in the monoclinic space group (P2_1)/m (No. 11) with a = 9.720(2) Å, b = 18.142(4) Å, c = 10.046(2) Å, β = 100.11(3)°, D_c = 1.339 g cm^(-3), and Z = 2; the complex cation, [Co(3-Cl-acacen)(NH_3)_2]^+, exhibits a slightly distorted octahedral coordination geometry. The distances between the cobalt atom and the two axial nitrogen donor atoms differ only slightly (1.960(6) and 1.951(6) Å) and are similar to Co−N distances found in cobalt−ammine complexes as well as the axial Co−N distances in [Co(acacen)(4-MeIm)_2]Br·1.5H_2O; the latter compound crystallizes in the triclinic space group P1̄ (No. 2) with a = 18.466(9) Å, b = 14.936(7) Å, c = 10.111(5)Å, α = 96.27(5)°, β = 94.12(5)°, γ = 112.78(5)°, D_c = 1.447 g cm^(-3), and Z = 4.
Additional Information
© 1997 American Chemical Society. Received September 18, 1996. A.B. thanks the Alexander von Humboldt Foundation for a postdoctoral fellowship. This work was supported by NSF, the Arnold and Mabel Beckman Foundation, and Redox Pharmaceutical Corp.Attached Files
Supplemental Material - ic2498.pdf
Files
Name | Size | Download all |
---|---|---|
md5:7e4754940ec42bf302ddae9259b578c0
|
803.1 kB | Preview Download |
Additional details
- Eprint ID
- 86665
- DOI
- 10.1021/ic961146v
- Resolver ID
- CaltechAUTHORS:20180529-112353490
- Alexander von Humboldt Foundation
- NSF
- Arnold and Mabel Beckman Foundation
- Redox Pharmaceutical Corporation
- Created
-
2018-05-29Created from EPrint's datestamp field
- Updated
-
2021-11-15Created from EPrint's last_modified field